Regulus Therapeutics Completes Enrollment in Phase 1b Kidney Disease Drug Trial
H.C. Wainwright Maintains Regulus Therapeutics(RGLS.US) With Buy Rating, Maintains Target Price $10
Express News | Regulus Therapeutics Inc: Remain on Track for an End of Phase 1 Meeting With FDA by End of 2024
Express News | Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1B Multiple-Ascending Dose (Mad) Clinical Trial of Rgls8429 for the Treatment of Patients With Autosomal Dominant Polycystic Kidney Disease (Adpkd)
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
Oppenheimer Reiterates Outperform on Regulus Therapeutics, Maintains $7 Price Target
Buy Rating Reaffirmed for Regulus Therapeutics Amidst Promising Clinical Data and Progress Towards Pivotal Trial
Regulus Therapeutics Q2 EPS $(0.17) Misses $(0.13) Estimate
Express News | Regulus Therapeutics Inc: Ended Q2 2024 With Cash, Cash Equivalents, and Investments of $95.9 Mln; Cash Runway Into H1 2026
Regulus Therapeutics | 10-Q: Q2 2024 Earnings Report
Express News | Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates
Express News | Regulus Therapeutics Q2 Operating Expenses USD 12.26 Million
Express News | Regulus Therapeutics Q2 Net Income USD -11.036 Million
Express News | Regulus Therapeutics Q2 Basic EPS USD -0.17
Express News | Regulus Therapeutics Q2 Pretax Profit USD -11.035 Million
Express News | Regulus Therapeutics Q2 Income From Operations USD -12.26 Million
Regulus Therapeutics 2Q Loss/Shr 17c >RGLS
Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference
Oppenheimer Maintains Regulus Therapeutics(RGLS.US) With Buy Rating, Maintains Target Price $7
Oppenheimer analyst Andreas Argyrides maintains $Regulus Therapeutics(RGLS.US)$ with a buy rating, and maintains the target price at $7.According to TipRanks data, the analyst has a success rate of 45